About 2,217,370 results

VIDEO: Differentiating glaucoma from nonglaucomatous neuro-ophthalmic disease

Feb 20th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Andrew G. Lee, MD, discusses ways to differentiate between glaucoma and nonglaucomatous neuro-ophthalmic disease.

VIDEO: Early keratoconus detection key for corneal cross-linking success

Feb 19th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Ronald R. Krueger, MD, discusses strategies for early detection of keratoconus and the benefits of performing cross-linking at an early stage.

VIDEO: Neuromodulators offer relief for patients with superior limbic keratoconjunctivitis

Feb 9th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Laura M. Periman, MD, discusses superior limbic keratoconjunctivitis and the potential use of neuromodulators to ease patients’ symptoms.

Proficiency, flexibility help match patients with appropriate MIGS device

Feb 7th, 2022 - WAIKOLOA, Hawaii — With several good MIGS options, the choice often comes down to matching the procedure with the patient, according to a presentation at Hawaiian Eye 2022. John Berdahl, MD, said devices such as the Hydrus microstent (Ivantis/Alcon) and the iStent (Glaukos) have shown efficacy in reducing IOP and medications in patients with glaucoma. “So, how do you choose?” Berdahl said. “I a...

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

VIDEO: Striving for ‘one and done’ with collagen cross-linking

Jan 26th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Kathryn M. Hatch, MD, explains why cornea specialists strive for “one and done” when treating keratoconus and other epithelial defects with collagen cross-linking.

VIDEO: ECP viable as stand-alone procedure, in combination with MIGS

Jan 25th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, Michael Greenwood, MD, discusses the benefits of adding endoscopic cyclophotocoagulation to any minimally invasive glaucoma surgery.

Be cautious if considering use of premium IOLs in patients with glaucoma

Jan 21st, 2022 - WAIKOLOA, Hawaii — Surgeons need to consider the risks and possible refractive outcomes before implanting a premium IOL in a patient with glaucoma, according to a presentation at Hawaiian Eye 2022. Nathan Radcliffe, MD, said that when a patient with glaucoma who already has a premium IOL experiences a problem, the IOL is rarely the issue. “I never remove the premium IOL because as bad as the gl...

Concomitant disease should be considered when treating progressive glaucoma

Jan 20th, 2022 - WAIKOLOA, Hawaii — Ophthalmologists should consider co-management of other diseases when treating progressive glaucoma, according to a speaker here. “I think that we need to remind ourselves, even as we rush through clinic, to think about the linkage to common disease that puts the optic nerve at risk,” Jeffrey L. Goldberg, MD, PhD, said at Hawaiian Eye 2022. To aid with co-management, he said,...

Glaucoma treatment should be tailored to individual patients

Jan 20th, 2022 - WAIKOLOA, Hawaii — Clinical research, personal experience, physician skill set, patient factors and goals all influence the decision to perform trabeculectomy or use a tube shunt, a speaker said here at Hawaiian Eye 2022. “Individualize the treatment choice to the patient in front of you,” Brian E. Flowers, MD, said. If the IOP target is low or if the patient is younger or has medication tolera...

Retinal fluorescence imaging helps identify early functional changes

Jan 19th, 2022 - WAIKOLOA, Hawaii — Fluorescence imaging can be an important tool for early detection of retinal diseases, according to a presentation at Retina 2022. Rishi P. Singh, MD, said that technologies such as fundus autofluorescence (FAF), fluorescence lifetime imaging ophthalmoscopy (FLIO) and oxidized flavoprotein fluorescence (FPF) provide opportunities to identify cell dysfunction before it occurs....

Advances may ease difficulties of visual field testing

Jan 19th, 2022 - WAIKOLOA, Hawaii — Visual field testing is important for detecting progression in patients with glaucoma, but some may have difficulty with the test process, according to a speaker here. “This is very true for the full threshold patterns, which require 15 minutes per eye,” Monica Ertel, MD, PhD, said at Hawaiian Eye 2022. Ertel discussed developments in visual field strategies, including visual...

Take steps to manage pseudoexfoliation glaucoma in cataract surgery

Jan 19th, 2022 - WAIKOLOA, Hawaii — Keep the cornea in mind and protect the endothelium when managing pseudoexfoliation glaucoma during cataract surgery, a presenter said here. “Consider femto if at all possible to decrease the ultrasound and combine with angle surgery, but skip the implants to save the cornea,” Malik Y. Kahook, MD, said at Hawaiian Eye 2022. The second key is to target the angle first and earl...

Consensus group provides imaging criteria for assessment of geographic atrophy

Jan 19th, 2022 - WAIKOLOA, Hawaii — In a series of published reports, the Classification of Atrophy Meeting group provided consensus-based imaging parameters for multimodal assessment of geographic atrophy. The group also revised the definitions of specific features of geographic atrophy (GA) and identified features that may predict progression to atrophy. “In the first CAM report, we described the imaging moda...

VIDEO: Intracameral bimatoprost implant helps reduce glaucoma medication burden

Jan 19th, 2022 - WAIKOLOA, Hawaii — At Hawaiian Eye 2022, I. Paul Singh, MD, discusses some of the advantages of the use of Durysta intracameral bimatoprost injection to lower IOP in patients with glaucoma. “What’s interesting about Durysta now, having about a year and a half experience with it is that although it releases bimatoprost for 4 months, the duration of effect in some patients can be 6 months, 9 mont...

Several pathways under investigation for dry AMD treatment

Jan 18th, 2022 - WAIKOLOA, Hawaii — Several pathways are under investigation for the treatment of dry age-related macular degeneration, according to a presentation at Retina 2022. “The big issue for us researchers is we don’t have a good animal model to test anything,” Peter K. Kaiser, MD, said. “We don’t have preclinical models that inform us if a drug is going to work or not because the animal that we use are...

Chang highlights new trends in antibiotic prophylaxis for endophthalmitis

Jan 18th, 2022 - WAIKOLOA, Hawaii — Just past the 15-year anniversary of the cefuroxime ESCRS trial, debate regarding antibiotic prophylaxis for endophthalmitis after cataract surgery continues. “When you have something controversial, it's nice to see what our colleagues are doing,” David F. Chang, MD, said at Hawaiian Eye 2022. To that end, surveys of ASCRS members conducted in 2007, 2014 and 2021 published in...

VIDEO: Special considerations needed for premium IOLs in patients with glaucoma

Jan 18th, 2022 - WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2022, John Berdahl, MD, of Vance Thompson Vision in Sioux Falls, South Dakota, spoke about premium and toric IOLs in patients with glaucoma. “I was actually quite surprised in an informal poll of the audience at how many surgeons did premium IOLs,” Berdahl said. “The vast majority of hands went up, but they actually stayed up...

Address ocular surface disease before surgery to optimize patient satisfaction

Jan 17th, 2022 - WAIKOLOA, Hawaii — Diagnosing and treating ocular surface disease preoperatively is one of the elements that contribute to elevated patient satisfaction postoperatively, Marjan Farid, MD, said at Hawaiian Eye 2022. “We know that 50% of patients, at least, who come in for cataract surgery are asymptomatic, but at least 80% of those patients have at least one sign of dry eye disease,” Farid said ...

Ocular oncology landscape ‘rapidly evolving’

Jan 17th, 2022 - WAIKOLOA, Hawaii — The landscape of ocular oncology is “rapidly evolving” in a way similar to medical oncology, a speaker said during a presentation here. At Hawaiian Eye 2022, Basil K. Williams Jr., MD, discussed how anterior segment OCT can be a “valid help adjunct” to clinical exams, although it is not a replacement for them. OCT can also help physicians differentiate between different lesio...

Medicare cuts, ASC rates, new FDA-approved drugs: Latest for 2022

Jan 17th, 2022 - WAIKOLOA, Hawaii — Medicare payment changes, ASC payment rates and new FDA approved drugs were a few of the topics discussed in a presentation on 2022 updates for ophthalmic practices at Hawaiian Eye 2022. Paul M. Larson, MBA, MMSC, COMT, CPC, COE, CPMA, a senior consultant from Corcoran Consulting Group, said that the Medicare Physician Fee Schedule was just updated a few weeks ago. “With the ...

How to avoid the perils of uveitis diagnostic management

Jan 16th, 2022 - WAIKOLOA, Hawaii — It is important for physicians to consider “the perils that dwell” in the diagnostic management of patients with uveitis, Steven Yeh, MD, said during a presentation at Hawaiian Eye 2022. “With these patients being very complex oftentimes, we really just don’t want to miss something,” Yeh said. To better identify “the pearls amongst the perils” in uveitis diagnosis, it is impo...

VIDEO: Dextenza helps reduce post-cataract surgery glaucoma drop burden

May 24th, 2021 - WAILEA, Hawaii — In this Hawaiian Eye 2021 video, Savak “Sev” Teymoorian, MD, MBA, explains how Dextenza (dexamethasone, Ocular Therapeutix) intracanalicular inserts can reduce drop burden in patients with glaucoma after cataract surgery.

VIDEO: Lee explains how to identify NMOSD in patients with optic neuritis

May 21st, 2021 - WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Andrew G. Lee, MD, discusses the important questions ophthalmologists should ask patients with optic neuritis to identify neuromyelitis optica spectrum disorder.

VIDEO: Durysta helps patients overcome challenge of instilling glaucoma drops

May 21st, 2021 - WAILEA, Hawaii — In this video at Hawaiian Eye 2021, Savak Teymoorian, MD, MBA, discusses how the Durysta bimatoprost implant 10 µg from Allergan obviates the need for patients with glaucoma to instill drops.

Home OCT with AI may be feasible for patients with wet AMD

May 18th, 2021 - WAILEA, Hawaii — The COVID-19 pandemic changed the way physicians monitor age-related macular degeneration, and Nancy M. Holekamp, MD, believes those changes are here to stay. “We all learned that remote monitoring of our patients is desirable, even if there isn’t a pandemic,” she said in her presentation at Retina 2021. “It currently exists with monitoring patients with intermediate AMD, and t...

Aqueous humor holds potential as surrogate biopsy of retinoblastoma

May 14th, 2021 - WAILEA, Hawaii — New research using liquid biopsy presents a new opportunity for treating retinoblastoma. Currently, retinoblastoma is diagnosed clinically, without biopsy, to avoid extraocular tumor seeding. In ongoing research, Jesse L. Berry, MD, of USC Roski Eye Institute, and colleagues are finding potential for using aqueous humor, obtained safely, as a means of diagnosing retinoblastoma,...

VIDEO: Innovative technology reframes ‘controlled’ glaucoma

May 14th, 2021 - WAILEA, Hawaii — In this video from Hawaiian Eye, I. Paul Singh, MD, discusses how innovative technology has changed his definition of controlled glaucoma.

Weigh pros, cons of at-home IOP measurements

May 13th, 2021 - WAILEA, Hawaii — Glaucoma patients may ask for ways to monitor IOP between visits, but ophthalmologists should weigh benefits and drawbacks of at-home monitoring options, according to speakers at Hawaiian Eye 2021. “I have that question all the time, actually,” Sahar Bedrood, MD, PhD, said. “Some of my patients are significantly worried, so they come in.” Options for at-home eye care include re...

Shields receives Philip M. Corboy, MD, award

May 13th, 2021 - WAILEA, Hawaii — M. Bruce Shields, MD, was awarded the Philip M. Corboy, MD, Memorial Award for Distinguished Service to Ophthalmology at Hawaiian Eye 2021. Shields was unable to attend the meeting but accepted the award by way of a recorded video. “I sure wish we could be with you, but I’m grateful to the organizing committee of the Hawaiian Eye meeting that we can at least join you virtually,...

VIDEO: Bedrood discusses experience with iStent inject

May 12th, 2021 - WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Sahar Bedrood, MD, PhD, discusses how she has incorporated the iStent inject (Glaukos) into her practice, patient selection and the benefits of using the device in those with glaucoma.

VIDEO: Samuelson discusses best practices in combined glaucoma, cataract cases

May 12th, 2021 - WAILEA, Hawaii — In this video from Hawaiian Eye, Thomas W. Samuelson, MD, discusses the nuanced decision-making that goes into deciding which surgical interventions to use in patients with glaucoma who are also in need of cataract surgery.

VIDEO: Reasons to crosslink patients with keratoconus before cataract surgery

May 11th, 2021 - WAILEA, Hawaii — In this video from Hawaiian Eye, Brandon D. Ayres, MD, discusses why patients with keratoconus and cataract should receive corneal collagen crosslinking prior to cataract surgery.

VIDEO: Steps to take to implement MIGS into an ophthalmology practice

May 10th, 2021 - WAILEA, Hawaii — At Hawaiian Eye 2021, Deborah G. Ristvedt, DO, discusses how to implement minimally invasive glaucoma surgery techniques in a surgical practice using the newest technologies.

RECOVER Researchers Express Hope and Frustration in Their Study of Long COVID
MedPage Today; DePeau-Wilson M.

Jul 23rd, 2022 - Slow enrollment has led to simmering frustrations over the progress and potential of the NIH's RECOVER Initiative, the research consortium focused on studying post-acute sequelae of SARS-CoV-2, or long COVID, according to researchers and leaders within the initiative. The RECOVER Initiative was designed to support research on long COVID across the U.S., including among every group of people ...

Natural History and Development of Spondyloarthritis

Sep 28th, 2022 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Sep 9th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Arthritis & Rheumatology (Hoboken, N.J.); Fraenkel L, Bathon JM et. al.

Jun 9th, 2021 - To develop updated guidelines for the pharmacologic management of rheumatoid arthritis. We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising c...

Fluconazole - fluconazole tablet-REMEDYREPACK INC.

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

2019 Update of the American College of Rheumatology/Spondylitis Association of America/...
Arthritis & Rheumatology (Hoboken, N.J.); Ward MM, Deodhar A et. al.

Aug 23rd, 2019 - To update evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). We conducted updated systematic literature reviews for 20 clinical questions on pharmacologic treatment addressed in the 2015 guidelines, and for 26 new questions on pharmacologic treatment, treat-to-target strategy, and use of imaging. New q...

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
The New England Journal of Medicine; Charness ME, .

Sep 15th, 2022 - Nirmatrelvir is an inhibitor of the main protease in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has been shown to block viral replication and reduce disease severity in unvaccinated persons at risk for the progression of coronavirus disease 2019 (Covid-19).1 Here, we describe the occurrence of rebound symptoms and viral replication after treatment with nirmatrelvir combin...

How deadly is monkeypox? What scientists know
Nature Kozlov M.

Sep 13th, 2022 - The global monkeypox outbreak has caused some deaths, but the death rate is lower than expected from historical data — and scientists are breathing a cautious sigh of relief. Out of more than 57,000 people confirmed to have had monkeypox infections, at least 22 have died, representing a death rate of about 0.04%. That’s significantly less than the 1–3% that has been reported during outbreaks ca...

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
BMJ Jolliffe D A, Holt H et. al.

Sep 7th, 2022 - The covid-19 pandemic has refocused attention on strategies to prevent acute respiratory tract infection. Although vaccination against SARS-CoV-2 represents the mainstay for disease control, its effectiveness at a global level is compromised by factors such as cost, availability, vaccine hesitancy, vaccine failure, and vaccine escape.123 Complementary, low cost approaches to enhance immunity to...

Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post–COVID-19 Conditions
JAMA Psychiatry; Wang S, Quan L et. al.

Sep 7th, 2022 - Postacute sequelae of SARS-CoV-2, sometimes called long COVID, are defined as signs and symptoms consistent with COVID-19 that extend beyond 4 weeks from onset of infection and constitute an emerging health issue.1 Common symptoms of post–COVID-19 conditions include fatigue, brain fog, dyspnea, digestive issues, loss of taste and smell, and depression,2,3 which may persist for months after init...

Myocarditis After BNT162b2 COVID-19 Third Booster Vaccine in Israel
Circulation Mevorach D, .

Sep 7th, 2022

How nasal-spray vaccines could change the pandemic
Nature Waltz E.

Sep 6th, 2022 - Are sprays the future of COVID-19 vaccines? That’s the hope of dozens of research groups and companies working on new kinds of inoculation. Rather than relying on injections, these use sprays or drops administered through the nose or mouth that aim to improve protection against the virus SARS-CoV-2.

Cortrosyn - cosyntropin injection, powder, lyophilized, for solution-Amphastar Pharmaceuticals, Inc.

Dec 1st, 2022 - CORTROSYN® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION ...

Evidence of human-to-dog transmission of monkeypox virus
The Lancet; Seang S, .

Aug 27th, 2022 - Human monkeypox virus is spreading in Europe and the USA among individuals who have not travelled to endemic areas.1 On July 23, 2022, monkeypox was declared a Public Health Emergency of International Concern by WHO Director-General Tedros Adhanom Ghebreyesus.2 Human-to-human transmission of monkeypox virus usually occurs through close contact with the lesions, body fluids, and respiratory drop...

Could tiny blood clots cause long COVID’s puzzling symptoms?
Nature Willyard C.

Aug 24th, 2022 - When Lara Hawthorne, an illustrator in Bristol, UK, began developing strange symptoms after having COVID-19, she hoped that they weren’t due to the virus. Her initial illness had been mild. “I’ve been triple vaccinated. I felt quite protected,” she says. But months later, she was still sick with a variety of often debilitating symptoms: earaches, tinnitus, congestion, headaches, vertigo, heart ...

Monkeypox: Fractional vaccine doses will be piloted as new treatment trial launches
BMJ Mahase E.

Aug 23rd, 2022 - Smaller doses of the smallpox vaccine, used to provide protection against monkeypox, will be piloted at NHS sites in London and Manchester to maximise supply, the UK Health Security Agency (UKHSA) has announced. In the pilot scheme—which will take place at Chelsea and Westminster NHS Foundation Trust, Central and North West London NHS Foundation Trust, and Locala Health and Wellbeing in Grea...

US CDC announces major changes after criticism of its responses to covid-19 and monkeypox
BMJ Tanne JH.

Aug 23rd, 2022 - The US national public health agency, the Centers for Disease Control and Prevention (CDC), will make major changes to its structure and systems in the light of a review of its emergency response to the covid-19 pandemic.

COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status
JAMA Internal Medicine; Butt AA, Dargham SR et. al.

Aug 22nd, 2022 - Infection with the SARS-CoV-2 Omicron variant is associated with less severe disease compared with the Delta variant.1-3 Two main Omicron sublineages—BA.1 and BA.2—have variable geographic distribution. In Qatar, BA.1 was initially predominant but was quickly replaced by BA.2 as the predominant sublineage. This study sought to determine and compare the severity of SARS-CoV-2 infection among per...

Which COVID boosters to take and when: a guide for the perplexed
Nature Ledford H.

Aug 19th, 2022 - The next generation of COVID-19 vaccines is on its way, but those shots will be looking to take a seat at an already crowded table. On the menu in some countries this autumn will be the familiar standards — mRNA and protein vaccines based on the spike protein from the ancestral version of SARS-CoV-2, which ushered in the pandemic. Alongside them will be a smattering of new specials, includin...

CDC Examines Monkeypox's Ability to Linger on Home Surfaces
MedPage Today; Hein I.

Aug 19th, 2022 - Commonly used household surfaces in the Utah home of two infected and symptomatic monkeypox patients were covered with PCR-detected virus, yet no samples were culturable, according to a CDC investigation.

High-Contact Object and Surface Contamination in a Household of Persons with Monkeypox Virus Infection — Utah, June 2022
MMWR and Morbidity and Mortality Weekly Report; Pfeiffer JA, Collingwood A et. al.

Aug 19th, 2022 - In May 2022, the Salt Lake County Health Department reported two real-time polymerase chain reaction (PCR)–confirmed travel-associated cases of monkeypox to the Utah Department of Health and Human Services (UDHHS). The two persons with monkeypox (patients A and B) lived together without other housemates. Both persons experienced prodromal symptoms (e.g., fatigue and body aches).

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
The New England Journal of Medicine; Bramante CT, .

Aug 18th, 2022 - Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients
The Lancet Psychiatry; Taquet M, .

Aug 17th, 2022 - COVID-19 is associated with increased risks of neurological and psychiatric sequelae in the weeks and months thereafter. How long these risks remain, whether they affect children and adults similarly, and whether SARS-CoV-2 variants differ in their risk profiles remains unclear.

Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity
JAMA Network Open; Joung SY, Ebinger JE et. al.

Aug 17th, 2022 - The rapid spread of the SARS-CoV-2 Omicron variant across communities worldwide has been attributed to several factors, including transmissibility features of the viral variant, limited coverage by available vaccines, and changes in face mask use and socializing behaviors.1,2 In particular, alterations of the Omicron variant have been implicated because of its greater transmissibility compared ...

How much virus does a person with COVID exhale? New research has answers
Nature Prillaman M.

Aug 17th, 2022 - People infected with the highly transmissible Alpha, Delta and Omicron variants of SARS-CoV-2 spew out higher amounts of virus than do those infected with other variants, according to a study1. Furthermore, individuals who contract COVID-19 after vaccination, and even after a booster dose, still shed virus into the air.

Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater — New York, June–August 2022
Morbidity and Mortality Weekly Report (MMWR); Link-Gelles R, Lutterloh E et. al.

Aug 16th, 2022 - On July 18, 2022, the New York State Department of Health (NYSDOH) notified CDC of detection of poliovirus type 2 in stool specimens from an unvaccinated immunocompetent young adult from Rockland County, New York, who was experiencing acute flaccid weakness. The patient initially experienced fever, neck stiffness, gastrointestinal symptoms, and limb weakness. The patient was hospitalized with p...

Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France
Annals of Internal Medicine; Ferré VM, .

Aug 16th, 2022 - Background: A monkeypox virus (MPXV) outbreak emerged in May 2022, affecting mostly men who have sex with men (MSM). Although most infections were characterized by cutaneous lesions, a recent report described 3 asymptomatic men with no cutaneous lesions but with positive results on anorectal MPXV polymerase chain reaction (PCR) testing (1).

Blood abnormalities found in people with Long Covid
Science Couzin-Frankel J.

Aug 16th, 2022 - An ambitious study of people with Long Covid, the mysterious, disabling symptoms that can trail a SARS-CoV-2 infection, has turned up a host of abnormalities in their blood. The clues add to a body of evidence hinting at drivers of the condition and potential treatments worth testing. They also suggest that, as many scientists and patients have suspected, Long Covid shares certain features with...

Risk of SARS-CoV-2 Acquisition in Health Care Workers According to Cumulative Patient Exposure and Preferred Mask Type
JAMA Network Open; Dörr T, Haller S et. al.

Aug 15th, 2022 - Health care workers (HCWs) are at increased risk for acquiring SARS-CoV-2 infection,1 raising the issue of adequate protective measures. Although scientific evidence regarding the benefit of respirator vs surgical masks is sparse,2,3 a previous study has suggested that respirator masks (ie, FFP2) may offer additional protection to HCW with frequent COVID-19-patient exposure.4 In this follow-up ...

Idiopathic Pulmonary Capillaritis Within the Spectrum of Pediatric Diffuse Alveolar Hemorrhage
Angela Chun, Tiphanie vogel, Andrea Ramirez et. al.

Nov 14th, 2022 - Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome with bleeding from the pulmonary microvasculature. It is classified as pulmonary capillaritis if histology shows neutrophilic invasion with fibrinoid necrosis of capillary walls. This can occur secondary to systemic autoimmune disease or in isolation as idiopathic pulmonary capillaritis (IPC). There is a paucit...

Characterizing Phenotypic Changes by SARS-CoV-2 Variant in Multisystem Inflammatory Syndrome in Children (MIS-C): A Single Institution Case Series
Sandy D. Hong1 and Emma Leisinger, University of Iowa Stead Family Children's Hospital, Iowa City et. al.

Nov 14th, 2022 - Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a severe hyper-inflammatory condition associated with a recent SARS-CoV-2 infection. Case reports began in April of 2020 from Italy and the United Kingdom documenting cases of children with shock-like illness and features of Kawasaki Disease (KD). Epidemiologic data demonstrates a latent rise and peak of MIS-C cases ap...

Histopathological Patterns of Muscle Involvement and Clinical Correlations in a Retrospective Cohort of Scleroderma Patients
Noemie Le Gouellec, Louai Zaidan, Eric Hachulla et. al.

Nov 14th, 2022 - Background/Purpose: Muscle involvement in systemic sclerosis (SSc) has been shown to be heterogeneous. Histopathological pattern seems to be associated with prognosis, but studies evaluating the correlations between muscle involvement subtypes, clinical presentation and outcomes are scarce. The aim of this study was to evaluate the prognostic value of histopathological muscular type in SSc. Met...

Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
Shivani Rangaswamy, Lisa Christopher-Stine, Jemima Albayda et. al.

Nov 14th, 2022 - Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American myositis re...

Idiopathic Inflammatory Myopathies in Alaska Native/American Indian People in Alaska
Vivek Mehta and Elizabeth Ferucci, Alaska Native Tribal Health Consortium, Anchorage et. al.

Nov 14th, 2022 - Background/Purpose: Racial disparities have been in noted in various autoimmune disorders. Indigenous North American populations have higher prevalence and severity of a number of autoimmune disorders, but few studies have examined the clinical characteristics of Idiopathic Inflammatory Myopathies (IIM) in Indigenous North American populations. We sought to describe the clinical characteristics...

The Potential Diagnostic Value of C-X-C Motif Chemokine 13 (CXCL13) in Seronegative Arthritis
Silvia Piantoni, Fabrizio Angeli, Francesca Regola et. al.

Nov 14th, 2022 - Background/Purpose: The finding of circulating biomarkers in the field of chronic arthritis is still an unmet need, especially for the subgroup of seronegative arthritis [e.g., negative for anti-citrullinated peptides autoantibodies (ACPA) and/or rheumatoid factors (RF)]. In fact, in this clinical subset, there is a lack of soluble molecules which could help for a diagnostic or prognostic purpo...

Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Daniel Kass, Mehdi Nouraie, Yingze Zhang et. al.

Nov 14th, 2022 - Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding work from our group has shown that a number of serum protein biomarkers of IPF are shared with RA-ILD. We therefore assessed the expression o...

COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
Holly Dudley, megan O'Mara, Ann Auma et. al.

Nov 14th, 2022 - Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19 vaccine, are more commonly diagnosed with COVID-19 and have worse outcomes once infected. Some of these observations may in part be attributable to immune suppressive medications including steroids, Rit...

Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
Claire DAIEN, Vera Georgescu, Guillaume Decarriere et. al.

Nov 14th, 2022 - Background/Purpose: A systematic screening of multimorbidities is performed since 2014 at the Montpellier University Hospital in patients with chronic inflammatory rheumatic diseases (IRD). The objective of this work was to assess the impact of this screening on management of patients and hospitalization rate during a 3-year follow-up. Methods: Patients with IRD who benefit from the screening p...

Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Jonathan Li, Emily Mirizio, Katherine Buhler et. al.

Nov 14th, 2022 - Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral center and clinic, one of our main interests is to examine the properties of the Euroimmun™ Scleroderma Disease Profile in juvenile-onset scleroderma. These panels may be useful for p...

Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine Among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
amit ziv, Merav Heshin-Bekenstein, Ruby Haviv et. al.

Nov 14th, 2022 - Background/Purpose: Effectiveness of the BNT162b2 mRNA COVID-19 vaccine for adolescents with juvenile-onset inflammatory rheumatic diseases (IRD) is unknown. Several studies suggested attenuated immunogenicity in patients with IRD. This study evaluated the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing COVID-19 infection in adolescents with juvenile-onset IRD compared to cont...

Clinical Characteristics and Outcomes of Pediatric ANCA-Associated Vasculitis Patients: Single-Center Inception Cohort
Hyun Ho Lee, Lauren Blazek2 and Eveline Wu, The University of North Carolina Chapel Hill et. al.

Nov 14th, 2022 - Background/Purpose: ANCA associated vasculitis (AAV) is a chronic autoimmune disorder characterized by ANCA production and small vessel inflammation and necrosis. ANCA autoantigen targets include myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-ANCA). There is growing evidence that ANCA specificity may be more predictive of prognosis and outcome than clinical phenotype. Due to the scarcity of d...

Racial Disparities Influence Healthcare Utilization in Pediatric Rheumatology Clinic
William Soulsby1 and Emily von Scheven, University of California, San Francisco et. al.

Nov 14th, 2022 - Background/Purpose: Racial disparities are prevalent in chronic illness, including pediatric rheumatic diseases. Prior work has investigated the impact of race on disease activity and damage in rheumatic diseases, such as lupus, but has not studied its impact on healthcare utilization patterns. As part of an institutional effort at the University of California, San Francisco (UCSF) to understan...

Efficacy of the COVID-19 Vaccine in Pediatric Systemic Lupus Erythematosus Patients
Yi Shi, Catherine Park, Sangeeta Sule2 and Sun-Young Ahn et. al.

Nov 14th, 2022 - Background/Purpose: The COVID-19 virus has caused significant morbidity and mortality, despite introduction of the COVID vaccine. Immunocompromised patients have been shown to have reduced response to the COVID vaccine compared to healthy individuals. There is currently limited data on the responsiveness of pediatric systemic lupus erythematosus (SLE) patients to the COVID vaccine. Methods: To ...

Mice Do Not Develop CIA: Knocking out of Kv1.3 Renders CD4+TEMCells Resistant to Activation
Siba Raychaudhuri, Smriti Raychaudhuri2 and Heike Wulff, UC Davis et. al.

Nov 14th, 2022 - Background/Purpose: Engagement of the TCR triggers Ca++ influx through Ca++ channels. Ca++ influx is only possible with a counterbalancing K+ efflux through Kv1.3 and/or KCa3.1. Given its regulatory role in effector memory T cells, Kv1.3 is likely to play a critical role in the pathogenesis of T cell mediated autoimmune arthritis such as in rheumatoid arthritis (RA) and psoriatic arthritis (PsA...

Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients
Kristin Schmiedeberg, Irene Abela, Nicolas Vuilleumier et. al.

Nov 14th, 2022 - Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) on immunomodulatory therapies have a higher likelihood of an impaired vaccine-induced immune response following an mRNA anti-SARS-CoV-2 vaccine. Determination of anti-S1 levels may serve as a surrogate for protection and may guide when to schedule a subsequent vaccine dose but data regarding the optimal timepoint for assess...

Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
Ana Campar, Ana Sá, Bárbara Oliveira2 and António Marinho et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of systemic autoimmune disorders, comprising dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), inclusion body myositis (IBM) and overlap myositis in which antisynthetase syndrome (ASS) is included. Treatment remains empiric as no on-label drug has been approved so ...

Assessment of Antibody Levels to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) in Patients with Idiopathic Inflammatory Myopathies Receiving Treatment with Intravenous Immunoglobulin
Sangmee Bae, emmanuelle Faure-Kumar, Jennifer Wang et. al.

Nov 14th, 2022 - Background/Purpose: Antibodies to Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) have been reported in pooled donor plasma and intravenous immunoglobulin products (IVIG) since May 2020 (C Romero 2021 PMID 33606999). It is not known whether regular administration of IVIG increases circulating anti-SARS-CoV-2 antibodies (COVID ab). The current work evaluates COVID ab titers in patie...

Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Diane Zisa, Aliza Bloostein, Deanna Jannat-Khah et. al.

Nov 14th, 2022 - Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC abnormalities, known as the “scleroderma pattern,” has been well-described in patients with systemic sclerosis and demonstrated to have prognostic significance. The significance of these changes in p...

Efficacy of Immune-apheresis in Patients with Inflammatory Myopathies: A Case Series
Kastriot Kastrati, Hanien Rajab, Anna Rader et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic inflammatory myopathies (IIM) comprise a heterogenous group of acquired autoimmune diseases characterised by inflammation of muscle and affection of other organs, including lung and skin. Some cases of IIM are non-responsive to conventional treatment with glucocorticoids and DMARDs requiring treatment escalation. Only limited data on efficacy and safety of immune-...

Association Study Between anti-TIF1γ Antibody and Development of Neoplasia in Three Tertiary Hospitals
Marina Pavía Pascual, Isidro Jarque Canalias, Jose Luis Morell et. al.

Nov 14th, 2022 - Background/Purpose: Anti-transcriptional intermediary factor 1γ (anti-TIF 1γ) antibody is robustly linked with malignancy-associated dermatomyositis (DM) in adults, but its specificity varies widely between series. TIF 1γ can act either as a tumor promoter or suppressor and may act as an autoantigen. To investigate the association between anti-TIF 1γ antibody positivity and the development of n...

Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody P...
Richard Seto, Sangmee Bae1 and Christina Charles-Schoeman, University of California Los Angeles et. al.

Nov 14th, 2022 - Background/Purpose: Patients with dermatomyositis (DM) and antibodies (ab) to melanoma differentiation associated gene 5 (MDA5) share similar clinical characteristics to patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including high risk of fatal, rapidly progressive interstitial lung disease (RP-ILD). Nearly 50% of patients with COVID 19 have anti-MDA5 a...

Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease Suggesting a High Prevalence of Undiagnosed Autoimmune Connective Tissue Disease
Sarah Tansley, Caroline Cotton, Fionnuala McMorrow et. al.

Nov 14th, 2022 - Background/Purpose: In some patients, interstitial lung disease (ILD) may be the dominant or even sole overt manifestation of an otherwise unrecognised autoimmune connective tissue disease (CTD). Accurate diagnosis can be challenging given considerable overlap of the clinical, radiological and histological disease features. Distinguishing CTD related ILD from idiopathic ILD, enables appropriate...

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Fahidah Alenzi, Shirish Sangle2 and Sanna Giovanni, Princess Nourah bint Abdulrahman University et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations. Rituximab has been shown to be effective in refractory IIM. The aim was to describe myositis specific autoantibodies (MSA) associated clinical and laboratory characteristics including...

Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
Haruna Matsuo, Toshimasa Shimizu, Tomohiro Koga et. al.

Nov 14th, 2022 - Background/Purpose: Muscle inflammation is a major clinical manifestation in patients with polymyositis/dermatomyositis (PM/DM). Phenotypes of PM/DM patients, especially those with interstitial lung diseases, are known to be classified through different subsets of autoantibodies, however, there are few studies evaluating muscle inflammation by serum biomarkers. The aim of this study is to ident...

Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys
Naveen R, Mrudula Joshi, Parikshit Sen et. al.

Nov 14th, 2022 - Background/Purpose: Patients with comorbidities and active rheumatic disease have increased morbidity and hospitalization following SARS-CoV-2 infection. While vaccination has decreased this, many unknown factors still influence COVID-19 vaccine hesitancy. The data on predictors of vaccine hesitancy is regional and scarce. We aimed to analyze the factors influencing vaccine hesitancy in 2022 an...

Analysis of the Association Between the Atrophic Factors Tripartite Motif Containing (TRIM) 63 and Atrogin-1 and the Clinical and Inflammatory Features of Patients with Idiopathic Inflammatory Myop...
jiram torres-Ruiz, Abdiel Absalón-Aguilar, Juan Alberto Reyes-Islas et. al.

Nov 14th, 2022 - Background/Purpose: Muscle atrophy is mediated by the ubiquitination of myofilaments by two ubiquitin ligases called Tripartite Motif Containing (TRIM) 63 and Atrogin-1, which are induced by inflammation and interferons (IFN). Muscle atrophy is the main cause of disability in patients with idiopathic inflammatory myopathies (IIM), but notwithstanding its relevance, the expression of TRIM63 and ...

Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity
Christopher Costin, Gabrielle Morgan, Amer Khojah3 and Lauren Pachman et. al.

Nov 14th, 2022 - Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune pathophysiology through the production of pathogenic autoantibodies. BAFF has been previously evaluated in the Japanese MDA5-JDM population and found to associate with the presence of rapidly progressive ILD (interstitial lung diseas...

Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
Shane Bruckner, Kassidy Banford, hannah Bulgart et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal muscle structure and function. Our previous work generated a robust model of inflammatory myositis by combining a mouse with impaired sarcolemmal membrane repair synaptotagmin VII (SytVII)-/- with a mous...

Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
Leona Ling, Steven Tyler, Christopher J. Beneduce et. al.

Nov 14th, 2022 - Background/Purpose: Nipocalimab, a fully human, effectorless IgG1 anti-neonatal Fc receptor (FcRn) monoclonal antibody, binds to FcRn with high affinity which prevents IgG recycling, leading to reduced serum levels of total IgGs, including pathogenic IgG autoantibodies. Rapid, sustained lowering of IgG was observed in the phase 2 VIVACITY study in generalized myasthenia gravis (gMG) and in phas...

Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez, Meena Sharma, Rui Feng et. al.

Nov 14th, 2022 - Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a cannabinoid type 2 receptor agonist that activates the resolution phase of inflammation. Results from DETERMINE, a Phase 3 trial of lenabasum, demonstrated improvement in CDASI activity (CDASI-A) scores with t...

B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
Christopher Costin, Gabrielle Morgan, Amer Khojah3 and Lauren Pachman et. al.

Nov 14th, 2022 - Background/Purpose: Juvenile Dermatomyositis(JDM) is heterogenous disease with many presentations. The underlying immune pathophysiology of JDM remains complex with varying phenotypes. B Cells remain a critical element in the pathophysiology both through the production of pathogenic antibodies but also as a target for the treatment of JDM. In order to better understand the role of B Cells in JD...

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Nilesh Kodali, Thomas Vazquez, DeAnna Diaz et. al.

Nov 14th, 2022 - Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed as a potential treatment to reduce inflammation in DM. Additional research has also shown that lenabasum also exerts its anti-inflammatory effects through the binding of peroxisome proliferator-activated receptor ...

Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
Jun Nakamura, Takao Nagashima and Kojiro Sato, Jichi Medical University et. al.

Nov 14th, 2022 - Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although serum ferritin has been reported as a prognostic marker for ILD among patients with anti-MDA5 antibody positive DM, serum ferritin levels does not neces...

Polymyositis/Dermatomyositis Readmissions: Analysis of the Nationwide Readmission Database
Ehizogie Edigin, Amy Trang, Sandhya Shri Kannayiram et. al.

Nov 14th, 2022 - Background/Purpose: Polymyositis (PM)/ Dermatomyositis (DM) is a chronic immune-mediated myositis characterized by relapses that can lead to frequent hospitalizations. There is a scarcity of national population-based studies on PM)/DM readmissions in the United States (US). In this study, we aim to describe the rates, reasons for readmissions, and characteristics of readmissions for adults hosp...

Racial Disparities in Diagnosis and Treatment of Patients with Dermatomyositis of Different Skin Tones
Hillary Weisleder, Ana Valle, Xianhong Xie2 and Shereen Mahmood et. al.

Nov 14th, 2022 - Background/Purpose: A lack of education in dermatopathology of non-white skin is of growing concern in the field of medical education. Diseases such as Dermatomyositis (DM) with pathognomonic dermatological features rely on swift recognition for diagnosis and treatment. There are no studies comparing detection and treatment initiation in patients with DM of different races and ethnicities. Our ...

Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
Paul Dellaripa, Paul Hoover and Tracy Doyle, Brigham and Women's Hospital et. al.

Nov 14th, 2022 - Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in the lung and prevent remodeling that can lead to fibrosis. While tapering regimens for steroids are part of the standard of care in CTD-ILD, there is no significant experience on outcomes in patients who taper stero...